Case Studies

Medical Science Liaisons are key points of contact at point of care and with payers to communicate key scientific information.  To provide its client with a strong and informed MSL team, IP developed customized training solutions to ensure a cohesive approach to stakeholder engagement. 

Conferences provide an important opportunity to engage with multiple stakeholders as large groups or in smaller 1:1 settings.  IP leveraged its expertise to coordinate multiple types of engagements and gather key insights for its client.

In order to develop an engagement plan for a stakeholder community which was growing and complex, IP identified and engaged multiple tiers of opinion leaders ensuring the client was able to reach a broad customer audience.

IP leveraged its Medical Affairs expertise and relationships with key opinion leaders to support a clinician-led effort to draw attention ...

IP leveraged its Medical Affairs expertise and experience supporting more than 70 submissions to key oncology clinical practice guidelines to advocate for the inclusion of a test that predicts the benefit of therapy, resulting in broad and appropriate access for patients. 

The Challenge A biopharmaceutical company has in-licensed a new drug that ...

The Challenge A biopharmaceutical company wants to shift patients indicated for their ...

The Challenge A biopharmaceutical company with a novel targeted treatment in phase 1/2A wants to ...

A large, multinational pharmaceutical company was looking to incorporate the patient voice across all stages of product development for their entire portfolio of oncology/hematology products. Their team needed support from a partner with the expertise to reach patients and advocacy organizations, and to develop an overall strategy for their advocacy relations team.

A ground-breaking medical device, although recognized by major clinical compendia, was lacking the appropriate Current Procedural Terminology (CPT) codes. This created hesitancy among providers, who feared they would not be reimbursed or prescribing this supportive care technology for their patients.

To ensure broad access for their supportive care technology, a European-based medical device company looking to enter the US market sought guidance and support in understanding the US payer system and how to gain buy-in from US healthcare providers.

A clinical-stage pharmaceutical company faced a unique barrier in bringing its first product to market—seeking pan-tumor approval based on a genetic marker, rather than a traditional approval based on cancer type. They subsequently sought recognition for the product across relevant clinical compendia.